Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Physiol ; 276(2): R283-9, 1999 02.
Artículo en Inglés | MEDLINE | ID: mdl-9950903

RESUMEN

Antenatal corticosteroid therapy reduces the incidence of intraventricular hemorrhage in premature infants. Enhanced microvascular integrity might provide protection against intraventricular hemorrhage. In the adult, there is evidence to suggest that the blood-brain barrier may be under hormonal control. We hypothesized that antenatal corticosteroids decrease blood-brain barrier permeability in the preterm ovine fetus. Chronically instrumented 120-day-gestation fetuses were studied 12 h after the last of four 6-mg dexamethasone (n = 5) or placebo (n = 6) injections had been given over 48 h to the ewes. Blood-brain barrier function was quantified with the blood-to-brain transfer constant (Ki) for alpha-aminoisobutyric acid (AIB). Ki was significantly lower across brain regions in the fetuses of ewes that received antenatal dexamethasone compared with placebo (ANOVA; interaction, F = 2.54, P < 0.004). In fetuses of dexamethasone- and placebo-treated ewes, Ki (microliter . g brain wt-1. min-1, mean +/- SD) was, respectively, 2.43 +/- 0.27 vs. 3.41 +/- 0.74 in the cortex, 4.46 +/- 0.49 vs. 5.29 +/- 0.85 in the cerebellum, and 3.70 +/- 0.49 vs. 5.11 +/- 0.70 in the medulla. We conclude that antenatal treatment with corticosteroids reduces blood-brain permeability in the ovine fetus.


Asunto(s)
Corticoesteroides/farmacología , Barrera Hematoencefálica/efectos de los fármacos , Permeabilidad Capilar/efectos de los fármacos , Feto/fisiología , Ácidos Aminoisobutíricos/antagonistas & inhibidores , Ácidos Aminoisobutíricos/sangre , Ácidos Aminoisobutíricos/metabolismo , Ácidos Aminoisobutíricos/farmacocinética , Animales , Encéfalo/embriología , Encéfalo/metabolismo , Dexametasona/farmacología , Feto/metabolismo , Glucocorticoides/farmacología , Ovinos/embriología , Distribución Tisular
2.
Metabolism ; 42(9): 1190-4, 1993 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8412774

RESUMEN

Sepsis and endotoxemia are associated with increased muscle protein breakdown and inhibited amino acid uptake. Glucocorticoids are important for the regulation of muscle protein breakdown in catabolic conditions; in contrast, the role of glucocorticoids in the regulation of muscle amino acid transport during sepsis or endotoxemia is not known. The present study was designed to test the role of glucocorticoids in the regulation of muscle amino acid uptake during endotoxemia. Amino acid transport, determined as uptake of 3H-alpha-aminoisobutyric acid (AIB) by incubated soleus muscles in vitro, was reduced by approximately 40% 2 hours after intraperitoneal (IP) injection of 10 micrograms/kg endotoxin in rats. Administration of 5 mg/kg of the glucocorticoid receptor antagonist RU 38486 2 hours before endotoxin injection did not affect the inhibition of amino acid uptake. In vitro addition of plasma from endotoxemic rats to incubated rat soleus muscles inhibited amino acid uptake by approximately 30%. This effect of endotoxic plasma also was noted when muscles were from rats that had been treated with RU 38486 and when RU 38486 was present in the incubation medium. Results confirm previous reports of reduced muscle amino acid transport during endotoxemia and of the presence of a circulating factor that inhibits muscle amino acid uptake in this condition. Data suggest that inhibited muscle amino acid transport during endotoxemia is not regulated by glucocorticoids.


Asunto(s)
Ácidos Aminoisobutíricos/farmacocinética , Endotoxinas/sangre , Glucocorticoides/fisiología , Músculos/metabolismo , Ácidos Aminoisobutíricos/antagonistas & inhibidores , Animales , Corticosterona/sangre , Corticosterona/farmacología , Escherichia coli , Masculino , Mifepristona/farmacología , Ratas , Ratas Sprague-Dawley
3.
Res Commun Chem Pathol Pharmacol ; 79(2): 195-208, 1993 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8451541

RESUMEN

We examined the effects of 6-hydroxydopamine (6-OHDA) treatment on the human neuroblastoma cell line SK-N-SH-SY5Y (SY5Y) and the rat pheochromocytoma cell line, PC12. Structural and metabolic integrity was tested by measuring the ability of cells to transport the non-metabolizable amino acid analogue [3H]-alpha-aminoisobutyric acid (AIB). We determined that treatment with 6-OHDA at concentrations of 49 microM and 62 microM inhibited 50% of the AIB uptake in SY5Y and PC12 cells, respectively. Inhibition of AIB uptake was prevented by the addition of catalase, but was not influenced by the addition of 1 mM dopamine. This indicated that cell damage resulted from the generation of H2O2 and was independent of the catecholamine uptake system. Effects directly on the catecholamine uptake system were observed by measuring the uptake of 3H-dopamine. In contrast to the effects on amino acid uptake, dopamine uptake was significantly inhibited by 6-OHDA treatment, and this inhibition was not prevented by the addition of catalase. The results indicate a Ki of 430 microM for inhibition of dopamine uptake by 6-OHDA treatment of PC12 cells. The results are consistent with a competitive irreversible inhibition of the dopamine uptake sites by 6-OHDA or one of its metabolites. Thus, the lack of a catecholamine uptake-dependent cellular toxicity appears to result from the direct inactivation of catecholamine uptake sites. Similarly, the inhibition of dopamine uptake in vivo by 6-OHDA may be explained, at least in part, by direct inactivation of dopamine uptake sites rather than exclusively by intracellular transport and action of 6-OHDA.


Asunto(s)
Antagonistas de Dopamina , Dopamina/metabolismo , Oxidopamina/farmacología , Neoplasias de las Glándulas Suprarrenales/metabolismo , Ácidos Aminoisobutíricos/antagonistas & inhibidores , Ácidos Aminoisobutíricos/metabolismo , Animales , Unión Competitiva , Transporte Biológico , Catalasa/farmacología , Humanos , Neuroblastoma/metabolismo , Feocromocitoma/metabolismo , Ratas , Células Tumorales Cultivadas
4.
J Lab Clin Med ; 86(6): 984-6, 1975 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-172569

RESUMEN

Initial rates of accumulation (Vi) of [3-14C] alpha-aminoisobutyric acid (AIB) by human leukemic leukocytes increased markedly and progressively during 240 minute incubations in amino acid-deficient media. Absolute increments were greater in blast cells from patients with acute lymphoblastic leukemia and with acute myeloblastic leukemia than in lymphocytes from patients with chronic lymphocytic leukemia, but per cent increments did not differ. Time-related increases appear to be restricted to an active mechanism for AIB entry and could not be attributed to cell damage, concomitant alterations in the incubation media, or progressive reduction in transinhibition of AIB entry. Studies with two cell populations revealed these increases to be associated with an augmented Vmax and a reduction in apparent Km, suggesting enhanced capacity and affinity of the transport system for AIB. Time-related increases failed to develop in two chronic lymphocytic leukemia (CLL) lymphocyte populations and were partially reduced in two leukemic blast cell populations during continuous exposure to high extracellular AIB concentrations. Hence, this phenomenon may represent an adaptive response to environmental amino acid deprivation. Adaptation may involve de novo protein and RNA synthesis, since it was not seen in cells which were treated with cycloheximide or actinomycin D. However, unlike previous observations in nonmalignant cells, once triggered, the adaptive response was not completely suppressed in leukemic cells which underwent a large degree of adaptation.


Asunto(s)
Ácidos Aminoisobutíricos/sangre , Leucemia Mieloide Aguda/metabolismo , Leucemia/sangre , Leucocitos/metabolismo , Enfermedad Aguda , Adenosina Trifosfato/metabolismo , Ácidos Aminoisobutíricos/antagonistas & inhibidores , Membrana Celular/fisiología , AMP Cíclico/metabolismo , Cicloheximida/farmacología , Dactinomicina/farmacología , Espacio Extracelular/metabolismo , Humanos , Líquido Intracelular/metabolismo , Cinética , Leucina/metabolismo , Leucemia Linfoide/sangre , Proteínas/metabolismo , Factores de Tiempo
5.
J Physiol ; 245(3): 521-36, 1975 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-1079871

RESUMEN

1. The isolated frog spinal cord was used to study the effects of picrotoxin, bicuculline, and strychnine on the responses of primary afferents to amino acids. Recording was by sucrose gap technique. 2. A series of neutral amino acids was found to depolarize primary afferents. Optimal activity was obtained by an amino acid whose carboxyl and amino groups were separated by a three-carbon chain length (i.e. GABA). Amino acids with shorter (i.e. beta-alanine, glycine) or longer (i.e. delta-aminovaleric acid, epsilon-aminocaproic acid) distances between the charged groups were less potent. Imidazoleacetic acid was the most potent depolarizing agent tested. 3. Picrotoxin and bicuculline antagonized the primary afferent depolarizations of a number of amino acids tested with equal specificity. Depolarizing responses to standard (10- minus 3 M) concentrations of beta-alanine and taurine were completely blocked by these convulsants, while depolarizations to 10- minus 3 gamma-aminobutyric acid (GABA) were only partially antagonized. Glycine responses were unaffected by these agentsk; Strychnine completely blocked beta-alanine and taurine depolarizations and incompletely antagonized several other neutral amino acids. GABA, glutamate, and glycine depolarizations were not affected. 5. These results suggest that there are at least three distinct populations of neutral amino acid receptors on primary afferent terminals: a GABA-like receptor, a taurine/beta-alanine receptor, and a glycine-like receptor. The strychnine resistance of the glycine responses indictaes that the primary afferent receptors for glycine differ from those on the somata of spinal neurones.


Asunto(s)
Aminoácidos/antagonistas & inhibidores , Convulsivantes/farmacología , Médula Espinal/efectos de los fármacos , Alanina/antagonistas & inhibidores , Aminocaproatos/antagonistas & inhibidores , Ácidos Aminoisobutíricos/antagonistas & inhibidores , Animales , Asparagina/antagonistas & inhibidores , Bicuculina/farmacología , Cistationina/antagonistas & inhibidores , Antagonistas de Aminoácidos Excitadores , Antagonistas del GABA , Glicina/antagonistas & inhibidores , Imidazoles/antagonistas & inhibidores , Técnicas In Vitro , Isomerismo , Leucina/antagonistas & inhibidores , Potenciales de la Membrana/efectos de los fármacos , Terminaciones Nerviosas/efectos de los fármacos , Neuronas Aferentes/efectos de los fármacos , Picrotoxina/farmacología , Rana pipiens , Serina/antagonistas & inhibidores , Estricnina/farmacología , Taurina/antagonistas & inhibidores , Treonina/antagonistas & inhibidores , Valina/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA